COVID-19 Vaccine Clinical Trials Begin Domestically... US Company Substance Vaccination Starts from the 16th

Researchers are conducting vaccine development experiments at the International Vaccine Institute (IVI) in Gwanak-gu, Seoul.

[Asia Economy Reporter Choi Dae-yeol] The vaccination with INO-4800, a COVID-19 vaccine candidate developed by the U.S. company Inovio, which is the first candidate in Korea to receive clinical trial approval, will begin on the 16th.

According to Bundang Seoul National University Hospital on the 15th, this clinical trial, commissioned by the International Vaccine Institute, is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and is being conducted at Bundang Seoul National University Hospital and Seoul National University Hospital. Bundang Seoul National University Hospital stated that a Phase 1 study evaluating safety, tolerability, and immunogenicity will begin with 40 healthy adults as subjects. At this hospital, the research team led by Professor Kim Ui-seok, head of the Infection Control Office and infectious diseases specialist, is in charge, while at Seoul National University Hospital, Professor Oh Myung-don, an infectious diseases specialist, is responsible.

After vaccination, immunogenicity acquisition such as antibody formation and safety will be evaluated over the course of one year. Previously, in the U.S., a Phase 1 trial began in April with 40 healthy adults. The hospital explained that the vaccination of subjects has been completed, and 94% of patients acquired immunity six weeks after vaccination, with side effects reported to be mild.

Professor Kim Ui-seok said, "Through international research evaluating the COVID-19 DNA vaccine, we hope to contribute to the development of a safer and more effective vaccine," adding, "We will do our best at every stage of research so that vaccine commercialization can help overcome the global COVID-19 pandemic as quickly as possible."

This content was produced with the assistance of AI translation services.